1. Home
  2. ALT vs ATYR Comparison

ALT vs ATYR Comparison

Compare ALT & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • ATYR
  • Stock Information
  • Founded
  • ALT 1997
  • ATYR 2005
  • Country
  • ALT United States
  • ATYR United States
  • Employees
  • ALT N/A
  • ATYR N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • ATYR Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ALT Health Care
  • ATYR Health Care
  • Exchange
  • ALT Nasdaq
  • ATYR Nasdaq
  • Market Cap
  • ALT 397.4M
  • ATYR 451.3M
  • IPO Year
  • ALT N/A
  • ATYR 2015
  • Fundamental
  • Price
  • ALT $4.19
  • ATYR $5.30
  • Analyst Decision
  • ALT Strong Buy
  • ATYR Strong Buy
  • Analyst Count
  • ALT 6
  • ATYR 6
  • Target Price
  • ALT $18.20
  • ATYR $20.20
  • AVG Volume (30 Days)
  • ALT 11.7M
  • ATYR 3.7M
  • Earning Date
  • ALT 08-07-2025
  • ATYR 08-12-2025
  • Dividend Yield
  • ALT N/A
  • ATYR N/A
  • EPS Growth
  • ALT N/A
  • ATYR N/A
  • EPS
  • ALT N/A
  • ATYR N/A
  • Revenue
  • ALT $20,000.00
  • ATYR N/A
  • Revenue This Year
  • ALT N/A
  • ATYR $551.06
  • Revenue Next Year
  • ALT $1,557,547.90
  • ATYR $1,874.58
  • P/E Ratio
  • ALT N/A
  • ATYR N/A
  • Revenue Growth
  • ALT N/A
  • ATYR N/A
  • 52 Week Low
  • ALT $2.90
  • ATYR $1.58
  • 52 Week High
  • ALT $11.16
  • ATYR $5.98
  • Technical
  • Relative Strength Index (RSI)
  • ALT 39.67
  • ATYR 56.28
  • Support Level
  • ALT $4.33
  • ATYR $5.07
  • Resistance Level
  • ALT $4.79
  • ATYR $5.58
  • Average True Range (ATR)
  • ALT 0.52
  • ATYR 0.39
  • MACD
  • ALT -0.16
  • ATYR -0.04
  • Stochastic Oscillator
  • ALT 26.92
  • ATYR 64.20

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About ATYR aTyr Pharma Inc. Common Stock

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

Share on Social Networks: